Abstract:Background: Patients with inflammatory bowel disease (IBD) are susceptible to viral infection, which may include SARS-CoV-2. The management of IBD and COVID-19 can be challenging, as the majority of patients are on some immunosuppressive medications. The aim of this study is to identify practice patterns, management strategy, and outcomes of IBD and COVID-19 with a world-wide survey of health care providers. Methods: The 22-item survey questionnaires were sent to the IBD community worldwide, including health care providers of IBD from epicenter countries at different time points, such as China, the United States, and Spain. Fifty IBD clinicians outside China were invited for the survey. The survey was sent to members of China Crohn’s and Colitis Foundation as a web blast.Results: Of 192 respondents (39 from outside China, 153 from China), 95 (49.5%) were IBD specialists or IBD colorectal surgeons. Thirty clinicians (15.6%) reported encountering COVID-19 patients during the pandemic, including 18 (9.4%) and 12 (5.2%) who cared for Crohn’s disease (CD) patients and ulcerative colitis (UC) patients with COVID-19, respectively. A majority of clinicians (N=152, 79.2%) believed that screening for SARS-CoV-2 was henceforth necessary before the initiation of biological therapy. Forty-two (21.9%) clinicians reported that they have switched infused biologics to an injectable biologic during the outbreak. Since the outbreak, 77 (40.1%) clinicians initiated systemic corticosteroids; 78 (40.6%) initiated immunomodulators; and 120 (62.5%) initiated biologics. Most clinicians [120/181 (66.3%)] recommended the continuation of corticosteroids or immunomodulators in all their IBD patients. Seventy-nine clinicians (43.6%) continued biologics in all their patients during the pandemic. One hundred and forty-seven (81.2%) respondents reported IBD flare-up of at least some of their patients and 106 reported IBD flare-up after continuation of immunosuppressive medications (ISM) (i.e. corticosteroids, immunomodulators, or biologics). One hundred and six (52.1%) reported disease progression of their IBD patients (i.e. IBD-related emergency room visit, hospitalization, or surgery) while continuing ISM; and 92 (47.9%) reported disease progression of IBD after discontinuing ISMs. Further analysis showed that continuation of ISMs or initiation of biologics during the pandemic were not associated with the increased number of patients with disease flare-up or progression. Of the 30 clinicians encountering COVID-19, 13 (43.3%) reported that their patients were not on corticosteroids; 14 (46.6%) reported that none of their patients were on immunomodulators; 13 (43.3%) reported that none of their patients was on any biologics. Three clinician reported COVID-19-associated deaths.Conclusions: Continued use of ISM was common in IBD clinicians during the outbreak. IBD patients can develop COVID-19 in the absence of the use of ISM. More than half of surveyed clinicians continued biologics and even initiated therapy during the pandemic. On the other hand, one third to close to one half of clinicians discontinued ISMs and none of them noticed any of their patients with disease flare or progression. The majority of clinicians recommended future screening for SARS-CoV-2 before the initiation of biological therapy.Funding Statement: None.Declaration of Interests: Dr. Yan Chen: None. Dr. Song Xu: None. Dr. Garrett Lawlor: Research grants for IBD fellowship from Janssen and Abbvie. Dr. Charles Bernstein: Has served on advisory boards for Abbvie Canada, Roche Canada, Janssen Canada, Takeda Canada, Pfizer Canada, consulted to Mylan Pharmaceuticals, has received educational grants from Abbvie Canada, Pfizer Canada, Takeda Canada, and Janssen Canada and has been on the speaker’s panel for Janssen Canada, Abbvie Canada, Medtronic Canada, and Takeda Canada. Dr. Francis A. Farraye: Consultant for BMS, Braintree Labs, Gilead, GSK, Innovation Pharmaceuticals, Janssen, Pfizer and Sebela. He sits on a DSMB for Lilly and Theravance. Dr. Marietta Iacucci: Research grant from Pentax, Olympus and Fujifilm. Consultant and speaker for Pentax, Abbvie and Jansen. Dr. Joseph Picoraro: No disclosure. Dr. Cindy Zhu: No financial conflicts of interest. Dr. Ravi P. Kiran: No disclosures. Dr. Bo Shen: consultant and speaker for Abbvie, Janssen, and Takeda,Ethics Approval Statement: The central institutional review board of study was approved by the ethics committee of the 2nd Hospital of Zhejiang University.

Suboptimal disease control and contributing factors in Italian IBD patients: The IBD-PODCAST Study

Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast study

P377 Proportion of IBD patients with suboptimal control in daily clinical practice – real-world evidence from the IBD Podcast study

P732 Lack of concordance between patient-reported, physician-reported and objective criteria-based identification of suboptimal control in IBD patients: IBD PODCAST study results

P1145 Assessing disease control in inflammatory bowel disease (IBD) – a real world cross-sectional study in the UK

Assessing disease control in inflammatory bowel disease: a real world cross-sectional study in the UK (PODCAST-IBD)

Effect of Suboptimal Disease Control on Patient Quality of Life: Real-World Data from the Observational IBD-PODCAST Canada Trial

P808 Use of intestinal ultrasound influences the proportion of suboptimally controlled patients: IBD Podcast Study results

P1127 Diagnostic delay and economic burden in IBD: a multicenter italian experience in patients treated with biologics

IBD-PODCAST Spain: A Close Look at Current Daily Clinical Practice in IBD Management

The Epidemiology and Clinical Management of Short Bowel Syndrome and Chronic Intestinal Failure in Crohn's Disease in Italy: An IG-IBD Survey

Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease

An IG-IBD Survey

Practice Patterns of Medical Management of Inflammatory Bowel Disease During Pandemic of COVID-19: A Global Survey of Health Care Providers

P467 Perception Gap Between Patients with Inflammatory Bowel Disease (IBD) and Physicians in China: A Cross-sectional Study

N06 Self-care in patients affected by inflammatory bowel disease: SELF-IBD observational study in a single center

Sexual dysfunctions in inflammatory bowel disease: role of Mediterranean diet and quality of life

Prevalence of Disease-Related Malnutrition and Micronutrients Deficit in Patients with Inflammatory Bowel Disease: A Multicentric Cross-Sectional Study by the GSMII (Inflammatory Bowel Disease Study Group)

P220 IBD-Disk: italian translation and validation in a population-based cohort

EXPLORING THE RELATIONSHIP BETWEEN PATIENT SYMPTOMS AND PROVIDER GOALS FOR MUCOSAL HEALING IN IBD: INSIGHTS FROM THE IBD QORUS SURVEY DATA

P1128 Reducing diagnostic delay of Extra-Intestinal Manifestations in patients with Inflammatory Bowel Disease: a comparative study between a multidisciplinary immune-mediated diseases outpatient clinic and conventional referral specialists